Alzheimer's Disease, MCI, MCI-AD, Early Stage Alzheimer's Disease
Conditions
Brief summary
The goal of this clinical trial is to assess the degree of improvement in cognitive functions, including memory, attention, thinking, executive and language functions in diagnosed patients MCI and AD taking dimethyl fumarate 480 mg daily compared to patients taking placebo. Participant will be 55 to 90 years old, both genders. The main question it aims to answer is: Changing the degree of cognitive improvement based on the RBANS score among patients diagnosed with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group.
Interventions
DRUGdimethyl fumarate
480 mg per day
Sponsors
Medical University of Lodz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men and women aged 55-90 years. 2. Patients diagnosed with mild cognitive impairment in Alzheimer's disease and mild to moderate Alzheimer's dementia (MMSE \>16) diagnosed based on NIA-AA criteria. 3. MMSE score from 17 to 30 points. 4. CDR score from 0.5 to 2. 5. The patient signs an informed, voluntary consent to participate in the study. 6. The patient has a close person/de facto guardian who agrees to help the patient during participation in the study. 7. At least 6 years of education. 8. In the case of anti-Alzheimer's drugs, the use of cholinesterase inhibitors is permitted provided that they are included at least 3 months before entering the study and used at a stable dose for at least 60 days before entering the study. In the case of memantine, its use is permitted provided that it is included at least 4 months before entering the study and used at a stable dose for at least 3 months before entering the study.
Exclusion criteria
1. Lack of informed voluntary consent to participate in the study. 2. Patients who cannot read or write. 3. Pregnant, breastfeeding or childbearing women who do not use effective contraception (hormonal contraception, surgical sterilization, intrauterine device, condom in combination with vaginal spermicide). 4. Participation in another clinical trial, currently or within 3 months prior to the screening visit. 5. Liver failure (i.e. cirrhosis or active liver disease), diagnosed acute or chronic hepatitis regardless of cause. 6. Chronic kidney disease with GFR below \< 60 ml/min/m2 7. Abnormal liver parameters: ALAT exceeding \> 2 times the upper limit of normal 8. Leukopenia (\<4000/mm3), granulocytopenia (\<1500/mm3) or lymphopenia (\<1000/mm3) regardless of the cause. 9. Severe agitation. 10. Mental retardation. 11. Delirium diagnosed according to DSM-5 criteria. 12. Diagnosis of neurological and neurodegenerative diseases other than Alzheimer's disease (multiple sclerosis, Parkinson's disease, Huntington's disease, previous stroke). 13. Presence of hemorrhagic foci in magnetic resonance imaging with a diameter of ≥ 2 cm3, more than three (3) ischemic stroke foci with a diameter of ≥ 1.5 cm3 or a single ischemic foci with a diameter of ≥ 2 cm3, presence of vascular malformations, aneurysms, subdural hematoma, normal pressure hydrocephalus, final decision at the discretion of the investigator. 14. Severe or uncontrolled somatic disease that could affect the course of the study (e.g. neoplastic, cardiovascular, respiratory, metabolic or digestive, severe renal failure, unstable type I or II diabetes, untreated or uncontrolled clinically significant hypertension). 15. Use of benzodiazepines or barbiturates within 1 week prior to screening. 16. Pharmacological immunosuppression. 17. Patients with bipolar disorder or psychotic disorders or any other psychiatric condition (current or past) that the Investigator believes interferes with the study. 18. Alcoholism or drug addiction as defined by DSM-5 within the past 5 years (dependent for more than 1 year and or in remission for less than 3 years). 19. Patients with any medical condition that, in the Investigator's judgment, is an exclusion criterion. 20. Thyroid hormone therapy initiated, discontinued, or modified within 3 months prior to screening visit. 21. Menopausal hormone replacement therapy initiated, discontinued, or modified within 3 months prior to screening visit. 22. Use of prohibited drugs in the study: Antineoplastic drugs (no studies). Immunosuppressive drugs (no studies). Corticosteroids (impact on project results). Live attenuated vaccines (no studies). Inactivated vaccines may be used. Benzodiazepines (impact on assessed endpoints). Other ethyl esters used orally or topically.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the degree of cognitive improvement based on the RBANS score among patients diagnosed with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group. | 15 months | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a neuropsychological measure used in the assessment of cognitive function in older adults, studies of mild cognitive impairment and Alzheimer's disease dementia, and studies evaluating the effectiveness of therapeutic interventions. The test generates index scores in five neurocognitive domains, as well as a Total Scale Index score. The RBANS is characterized by high sensitivity in detecting disease and assessing changes in scores during treatment in patients with MCI in the course of Alzheimer's disease. with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the impact of therapy on the presence of neuropsychiatric symptoms/behavioral disorders in patients using the Neuropsychiatric Inventory (NPI) scale and the Geriatric Depression Scale (GDS). | 15 months | — |
| Assessment of the impact of therapy on the quality of life of patients and their caregivers (EQ-5D scales; Zarit Burden Interview). | 12 months | — |
| Assessment of the effect of therapy on the reduction of the degree of brain atrophy in patients from the active group compared to the control group (MRI study). | 6 months | — |
| Assessment of the effect of therapy on the improvement of functional connections assessed in rs-fMRI and rs-EEG. | 15 months | EEG and MRI data will be processed using standard processing pipelines. The results will be a topographic map of the EEG frequency band distribution on the brain surface, temporal and time-frequency analyses based on FFT and wavelets, entropy analysis, and EEG coherence markers. Then, inverse localization of EEG signals generated on the scalp over the brain surface will be performed. Particular emphasis will be put on frontal structures and areas detected by MRI clustering. We will perform machine learning-based clustering of EEG and MRI data to detect significant features. CDR Clinical Dementia Rating Assessment score from 0.5 to 2 |
| Assessment of the safety of therapy | 15 months | — |
| Assessment of the impact of therapy on the daily functioning of patients - Alzheimer's Disease Cooperative Study - Activity of Daily Living (ADCS-ADL) scale. | 15 months | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the degree of improvement of cognitive functions using the MMSE and CDR scales. | 15 months | MMSE (Mini-Mental State Examination) score from 17 to 30 points CDR (The Clinical Dementia Rating) score from 0,5 to 2 points |
| Assessment of the effect of therapy on peripheral markers of oxidative stress and pro-inflammatory markers. | 6 months | — |
| Assessment of the degree of reduction of the MCI progression rate to dementia after the end of the clinical phase of the study. | 12 months | — |
Countries
Poland
Contacts
Primary ContactMedical University of Lodz Medical University of Lodz
Backup ContactJakub Kazmierski, PhD
Outcome results
None listed